BIOMAT Database Logo BIOMAT Database Logo

Phase I clinical studies of 7432-S, a new oral cephalosporin: safety and pharmacokinetics. 1988

M Nakashima, and T Uematsu, and Y Takiguchi, and A Mizuno, and M Iida, and T Yoshida, and S Yamamoto, and K Kitagawa, and T Oguma, and H Ishii
Department of Pharmacology, Hamamatsu University School of Medicine, Japan.

Phase I clinical studies of 7432-S, a new oral cephalosporin, including a randomized placebo-controlled trial were conducted with 40 healthy volunteers. In single-dose studies, 7432-S was orally administered at doses of 25, 50, 100, and 200 mg. The mean plasma levels peaked at 2.1 to 3.0 hours and reached 1.9, 3.6, 5.6, and 11.6 micrograms/ml, respectively. Linear correlation was observed between plasma AUC values and doses given. The half-lives of the plasma levels were 0.88 to 2.26 hours with a mean of 1.53 +/- 0.33 hours. The mean urinary recoveries were 67.5 to 75.2% of the dose within 24 hours. 7432-S was partially metabolized to 7432-S-trans which was excreted in urine at 7.2 to 9.2% of the doses. Study of the meal effect showed that AUC values and peak levels were not altered although the time to the peak levels was slightly prolonged. In multiple-dose studies, 100 mg of 7432-S twice daily for 2 weeks and 200 mg twice daily for 1 week were administered and there was no abnormal accumulation of 7432-S in plasma throughout the study. No significant differences were observed in plasma levels and urinary recoveries between single- and multiple-dose regimens. Clinical symptoms, physical tests, laboratory parameters, and fecal levels of vitamins K1 and K2 were in normal ranges. 7432-S was concluded to be safe and well tolerated.

UI MeSH Term Description Entries
D008297 Male Males
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D002511 Cephalosporins A group of broad-spectrum antibiotics first isolated from the Mediterranean fungus ACREMONIUM. They contain the beta-lactam moiety thia-azabicyclo-octenecarboxylic acid also called 7-aminocephalosporanic acid. Antibiotics, Cephalosporin,Cephalosporanic Acid,Cephalosporin,Cephalosporin Antibiotic,Cephalosporanic Acids,Acid, Cephalosporanic,Acids, Cephalosporanic,Antibiotic, Cephalosporin,Cephalosporin Antibiotics
D004032 Diet Regular course of eating and drinking adopted by a person or animal. Diets
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005243 Feces Excrement from the INTESTINES, containing unabsorbed solids, waste products, secretions, and BACTERIA of the DIGESTIVE SYSTEM.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077722 Ceftibuten A cephalosporin antibacterial agent that is used in the treatment of infections, including urinary-tract and respiratory-tract infections. 7-(2-(2-amino-4-thiazolyl)-4-carboxy-2-butenoylamino)-3-cephem-4-carboxylic acid,7432 S,7432-S,Cedax,SCH 39720,SCH-39720,SCH39720
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations

Related Publications

M Nakashima, and T Uematsu, and Y Takiguchi, and A Mizuno, and M Iida, and T Yoshida, and S Yamamoto, and K Kitagawa, and T Oguma, and H Ishii
Phase I Clinical Studies of S-1090: Safety and Pharmacokinetics.
January 1996, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy,
M Nakashima, and T Uematsu, and Y Takiguchi, and A Mizuno, and M Iida, and T Yoshida, and S Yamamoto, and K Kitagawa, and T Oguma, and H Ishii
[Pharmacokinetics and clinical studies of a new cephalosporin: cefamandole nafate].
May 1980, Minerva medica,
M Nakashima, and T Uematsu, and Y Takiguchi, and A Mizuno, and M Iida, and T Yoshida, and S Yamamoto, and K Kitagawa, and T Oguma, and H Ishii
In vitro evaluation of ceftibuten (7432-S, SCH 39720), a novel orally administered cephalosporin.
October 1988, Chemioterapia : international journal of the Mediterranean Society of Chemotherapy,
M Nakashima, and T Uematsu, and Y Takiguchi, and A Mizuno, and M Iida, and T Yoshida, and S Yamamoto, and K Kitagawa, and T Oguma, and H Ishii
Phase I study of single-dose BMY-28100, a new oral cephalosporin.
February 1990, Antimicrobial agents and chemotherapy,
M Nakashima, and T Uematsu, and Y Takiguchi, and A Mizuno, and M Iida, and T Yoshida, and S Yamamoto, and K Kitagawa, and T Oguma, and H Ishii
[Pharmacokinetics of cefadroxil, a new oral cephalosporin (author's transl)].
January 1980, Arzneimittel-Forschung,
M Nakashima, and T Uematsu, and Y Takiguchi, and A Mizuno, and M Iida, and T Yoshida, and S Yamamoto, and K Kitagawa, and T Oguma, and H Ishii
Clinical pharmacology phase I of cefazedone, a new cephalosporin, in healthy volunteers. II. Pharmacokinetics in comparison with cefazolin.
January 1979, Arzneimittel-Forschung,
M Nakashima, and T Uematsu, and Y Takiguchi, and A Mizuno, and M Iida, and T Yoshida, and S Yamamoto, and K Kitagawa, and T Oguma, and H Ishii
Antimicrobial activity, spectrum, and recommendations for disk diffusion susceptibility testing of ceftibuten (7432-S; SCH 39720), a new orally administered cephalosporin.
October 1988, Antimicrobial agents and chemotherapy,
M Nakashima, and T Uematsu, and Y Takiguchi, and A Mizuno, and M Iida, and T Yoshida, and S Yamamoto, and K Kitagawa, and T Oguma, and H Ishii
Safety, tolerability, and pharmacokinetics of oral (S)-oxiracetam in Chinese healthy volunteers: A randomized, double-blind, controlled phase I study.
January 2024, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences,
M Nakashima, and T Uematsu, and Y Takiguchi, and A Mizuno, and M Iida, and T Yoshida, and S Yamamoto, and K Kitagawa, and T Oguma, and H Ishii
Pharmacologic studies with cefaclor, a new oral cephalosporin.
April 1978, Journal of clinical pharmacology,
M Nakashima, and T Uematsu, and Y Takiguchi, and A Mizuno, and M Iida, and T Yoshida, and S Yamamoto, and K Kitagawa, and T Oguma, and H Ishii
Clinical evaluation of cephradine, a new oral cephalosporin.
February 1974, The American journal of the medical sciences,
Copied contents to your clipboard!